Literature DB >> 9617368

[Computerized tomography and magnetic resonance imaging findings in central neurocytoma].

M Freund1, O Jansen, K Geletneky, S Hähnel, K Sartor.   

Abstract

PURPOSE: Analysis of our CT and MRI findings in patients with central neurocytomas in comparison with the relevant literature.
MATERIALS AND METHODS: 5 patients were examined by CT and MRI. A retrospective analysis of the histologically confirmed tumors of our patient group and date from the literature was performed under the following criteria: 1. topography, 2. extent, 3. contrast medium behavior, 4. calcifications, 5. presence of intramural cysts, and 6. vascularization. These properties were evaluated according to a 5 point scale.
RESULTS: All tumors originated in the roof of a lateral ventricles with participation of the pellucid septum and extended intraventricularly (5/5), showed cystic components (5/5), and took up contrast medium (5/5). Contrast medium uptake was visible in both CT and MRI. In contrast, only three of the 5 tumors revealed calcifications (3/5) and these were better visible in CT than in MRI, no pathological vessels were detected. Because of its multi-planar representations and better soft-tissue contrast, MRI was superior to CT for the exact determination of origin and position of the tumors. The small cystic, inhomogenous appearance in T2-weighted images was considered to be an especially typical feature.
CONCLUSIONS: The typical appearance of central neurocytomas in CT and MRI provides information for the differential diagnosis from other intraventricular tumors. The definitive diagnosis is provided by neuropathological evaluation.

Entities:  

Mesh:

Year:  1998        PMID: 9617368     DOI: 10.1055/s-2007-1015168

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  1 in total

1.  Diagnostic value of six MRI features for central neurocytoma.

Authors:  Xiaodan Li; Liuji Guo; Sen Sheng; Yikai Xu; Lichao Ma; Xiang Xiao; Zhiguang Si; Yanping Chen; Yuankui Wu
Journal:  Eur Radiol       Date:  2018-04-30       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.